Anika Therapeutics, Inc. (ANIK) scores 51 out of 100 on boothcheck's 11-model valuation framework. Verdict: Avoid The estimated fair value is $1681636.19, representing a 11784316% margin of safety. Quantitative score: 59/100. Qualitative score: 50/100.
Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.